-
NAD+ and AMPK: Rethinking Energy-Stress Assays
2026-09-13
A translational framework for using Nicotinamide Adenine Dinucleotide (NAD+) to distinguish redox chemistry, enzymatic activity, and autophagy signaling in energy-stress research. By integrating recent AMPK–ULK1 findings, this article shows why NAD+ measurements should support—not substitute for—mechanistic pathway validation.
-
Making Neuroprotection Measurable After ICH
2026-09-12
A translational framework for connecting PI3K/AKT-linked neuroprotection after intracerebral hemorrhage with rigorous live/dead measurement using the Live-Dead Cell Staining Kit I (Calcein AM/PI).
-
BMX-IN-1: From Kinase Target to Lysosome Assay
2026-09-12
BMX-IN-1 is an irreversible BMX kinase inhibitor for connecting kinase signaling with lysosomal acidification and intracellular tuberculosis biology. This article provides a mechanism-led framework for choosing controls, interpreting phospho-signaling data, and separating host-directed promise from experimental proof.
-
Gemcitabine HCl: Reliable Cytotoxicity Assays
2026-09-11
This scenario-driven guide explains how Gemcitabine HCl, SKU A1402, can support reproducible DNA replication inhibition and in vitro cytotoxicity testing. It connects formulation, assay design, dose interpretation, storage, and preclinical tumor monitoring to practical laboratory decisions.
-
M344 in Neuroblastoma: Mechanisms and Tumor Control
2026-09-11
The 2025 study by Brumfield and colleagues connects elevated HDAC expression in advanced neuroblastoma with a therapeutically actionable response to M344, including histone hyperacetylation, G0/G1 arrest, caspase-mediated cell death, and reduced tumor growth. Its combination and metronomic dosing experiments suggest that schedule and treatment context may be as important as single-agent activity in preclinical neuroblastoma models.
-
From Finger Citron Biology to qPCR Strategy
2026-09-10
A translational framework for converting network pharmacology and HepG2 validation into reproducible transcript-level evidence, using HotStart 2X Green qPCR Master Mix to clarify assay specificity, workflow design, and the limits of mechanistic interpretation.
-
SAR131675 Workflow for VEGFR-3 Assays
2026-09-10
Build reproducible VEGFR-3 signaling, lymphatic endothelial survival, migration, and tumor-model workflows with SAR131675. Its ATP-competitive selectivity supports pathway attribution, while careful formulation controls help distinguish VEGFR-3 biology from precipitation, vehicle effects, and general cytotoxicity.
-
Ziprasidone HCl: From Receptors to Translation
2026-09-09
Ziprasidone HCl offers translational researchers a distinctive bridge between dopaminergic and serotonergic pharmacology, formulation science, and tumor-metabolism research. This article examines how ziprasidone hydrochloride can be evaluated as both a neuroscience tool and a reported GOT1-directed oncology research compound, with emphasis on assay design, permeability, and evidence boundaries.
-
DDI2–NFE2L1 Control of Ferroptosis
2026-09-09
The reference study shows that ferroptosis disrupts proteasome function and activates a DDI2-dependent NFE2L1 feedback response that restores protein quality control. Genetic loss or chemical inhibition of DDI2, including with nelfinavir, weakens this adaptation and sensitizes cells to ferroptotic death, identifying the pathway as a mechanistically defined target for further cancer and cell-death research.
-
Tamoxifen as a Precision Switch for Translational Biology
2026-09-08
Tamoxifen is more than an estrogen-pathway reagent: it is a context-dependent mechanistic probe and a temporal control tool for translational biology. This article connects conditional genetics with new evidence on persistent GZMK-expressing CD8+ T cells in recurrent airway inflammation.
-
Metronidazole for Reliable Cell Assays
2026-09-07
A scenario-based guide to using Metronidazole (SKU B1976) in viability, proliferation, transporter, and antimicrobial research. It explains concentration planning, solvent controls, assay interpretation, and practical criteria for selecting a well-characterized research reagent.
-
M344 in Neuroblastoma: Mechanism and Tumor Control
2026-09-07
The 2025 study evaluates M344 as a histone deacetylase inhibitor for neuroblastoma and connects increased histone acetylation with G0/G1 arrest, caspase-mediated cell death, reduced migration, and tumor-growth control. Its preclinical contribution is the integration of molecular, cellular, comparative, and combination-treatment evidence, including improved outcomes with metronomic dosing and selected chemotherapy combinations.
-
SB525334 for TGF-β1 Wound-Healing Studies
2026-09-05
SB525334 is a selective TGF-beta1 receptor inhibitor for testing how ALK5-dependent signaling separates reparative angiogenesis from pathological fibrosis. This article develops an assay framework linking Smad2/3 phosphorylation inhibition with spatial, temporal, and functional readouts in diabetic wound and renal disease models.
-
Staurosporine: Kinase Inhibitor & Apoptosis Tool
2026-09-04
Staurosporine is a broad-spectrum serine/threonine protein kinase inhibitor used to interrogate kinase signaling and induce apoptosis in cancer research. Its activity against PKC isoforms, selected receptor tyrosine kinases, and VEGF-driven angiogenesis supports mechanistic studies, but its broad target profile requires pathway-specific controls.
-
Nicotine Signaling and Chronic Kidney Disease
2026-09-04
Jain and Jaimes present a mechanistic synthesis showing that nicotine may contribute directly to chronic kidney disease progression through non-neuronal nicotinic acetylcholine receptors, oxidative stress, hemodynamic changes, and fibrosis. The review is useful for researchers because it connects clinical observations with animal-model evidence while identifying experimental gaps in separating nicotine effects from those of the broader cigarette-smoke mixture.